Latest Headlines
-
bit.bio Announces First Project Within Multi-Year Collaboration Agreement With The Michael J. Fox Foundation (MJFF) To Generate Human Cell Products For Research And Drug Discovery In Parkinson’s Disease
3/5/2024
bit.bio, the company coding human cells for novel cures, today announces the first project within a multi-year collaboration agreement with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to prioritise the development and delivery of a range of human cell products relevant to Parkinson’s disease (PD).
-
AnHeart Therapeutics And Innovent Announce China’s NMPA Has Accepted Second New Drug Application For Taletrectinib For First-Line Treatment Of ROS1-Positive Lung Cancer
3/4/2024
AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, and Innovent Biologics, Inc. (“Innovent”) a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted a second New Drug Application (NDA) for taletrectinib, a
-
Microsoft And 1910 Genetics Partner To Build The Infrastructure Layer For Drug Discovery And Development Using AI And High-Performance Computing
2/29/2024
1910 Genetics (or “1910”), the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation, today announced a new five-year commercial agreement and go-to-market collaboration with Microsoft to harness advanced artificial intelligence (AI) and next-generation, high-performance computing (HPC) to reverse 70 years of declining pharmaceutical R&D productivity.
-
Software Speeds Up Drug Development
2/29/2024
Sugars cover nearly all proteins present at the surface of the cells in our bodies, forming a shield around the proteins. Thus, these sugars influence how cells interact with their environment including pathogens, playing an important role in medical drug development.
-
Targeted Drug Shows Promising Ability In Treating Rare Head And Neck Cancers
2/29/2024
Experts at University of Michigan Health Rogel Cancer Center have conducted the first study evaluating the effectiveness of a targeted drug for patients with salivary gland cancers (SGC).
-
ARTHEx Biotech Receives IND Clearance From FDA To Initiate The Phase I-IIa ArthemiR™ Trial Of ATX-01 For Myotonic Dystrophy Type 1 (DM1)
2/28/2024
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced that the U.S. Food and Drug Administration (FDA) cleared the Company to initiate the Phase I-IIa ArthemiR™ study of ATX-01 for the treatment of Myotonic Dystrophy Type 1 (DM1).
-
Study Proposes Streamlined Approach To Developing Cancer Drugs
2/28/2024
Drug discovery can be a frustrating process of trial and error.
-
Ginkgo Bioworks Acquires Reverie Labs Platform, Enhancing AI-Driven Drug Discovery Capabilities For Customer Programs
2/28/2024
Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of Reverie Labs, which built and used AI/ML tools to accelerate drug discovery.
-
AbbVie And OSE Immunotherapeutics Announce Partnership To Develop A Novel Monoclonal Antibody For The Treatment Of Chronic Inflammation
2/28/2024
AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, today announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.
-
Curadev Announces First Treatment Cycle Completion For The First Patient Dosed In A Phase 1a/b Clinical Trial Of Its Allosteric STING Agonist CRD3874-SI In Patients With Advanced Cancer At Memorial Sloan Kettering Cancer Center In New York
2/27/2024
Curadev, a drug discovery and development company, announced today a significant milestone in its development of drugs targeting the immune system to treat cancer.